Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease

American Journal of Pathology

Volumn 155, Issue 3, 1999, Pages 853-862

  Lue, Lih Fen ^a   Kuo, Yu Min ^a   Roher, Alex E ^a   Brachova, Libuse ^a   Shen, Yong ^a   Sue, Lucia ^a   Beach, Thomas ^a   Kurth, Janice H ^b   Rydel, Russel E ^c   Rogers, Joseph ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b Phenogenex   (United States)

^c ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; DEMENTIA; ENTORHINAL CORTEX; GENE FREQUENCY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; NERVE DEGENERATION; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; VASCULAR AMYLOIDOSIS;

EID: 0032888131     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65184-X     Document Type: Article

References (33)

1. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L: Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1998, 38:1682-1687
2. Katzman R, Terry R, DeTeresa R, Brown T, Davis P, Fuld P, Renbing X, Peck A: Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988, 23:138-144
3. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, Aronson MK: Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1991, 13:179-189
4. Arrigada PA, Marzloff K, Hyman BT: Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42:1681-1688
5. Lue LF, Brachova L, Civin WH, Rogers J: Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 1996, 55:1083-1088
6. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968, 114:797-811
7. Dekosky ST: Searching for the holy grail. What is the structural correlate of cognition? Neurobiol Aging 1995, 16:285-304
8. Dickson DW, Ivanushkin A, Heitner J, Yen SH, Davies P: Apolipoprotein E immunoreactivity is increased in amyloid deposits of Alzheimer's disease, but not pathological aging or diffuse Lewy body disease. Research Advances in Alzheimer's Disease and Related Disordors. Edited by Iqbal K, Mortimer JA, Winblad B, Wisniewski HM. New York, John Wiley & Sons, 1995, pp 371-382
9. Mirra SS, Hyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L, participating CERAD neuropathologists: The consortium to establish a registry for Alzheimer's disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-481
10. Braak H, Braak F: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259
11. Scheff SW, DeKosky ST, Price DA: Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990, 11:29-37
12. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alteration in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580
13. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Roher AE: Elevated low density lipoprotein in Alzheimer's disease correlates with brain Aβ 42 levels. Biochem Biophys Res Commun 1998, 252:711-715
14. Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney MM, Little SP, Ball MJ: Chemical characterization of Aβ17-42 peptide, a component of the diffuse amyloid deposits of Alzheimer's disease. J Biol Chem 1994, 269:10987-10990
15. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE: Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996, 271:4077-4081
16. Galasko D, Chang L, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P: High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998, 55:937-945
17. Wisniewski HM, Bancher C, Barcikowska M, Wen GY, Currie J: Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease. Acta Neuropathol 1989, 78:337-347
18. Otvos L, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM: Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994, 39:669-673
19. Su JH, Cummings BJ, Cotman CW: Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res 1996, 739:79-87
20. Harrington CR, Louwagie J, Rossau R, Vanmechelen E, Perry RH, Perry EK, Xuereb JH, Roth M, Wischik CM: Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types: significance for etiological theories of Alzheimer's disease. Am J Pathol 1994, 145:1472-1484
21. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990, 31:545-548
22. Sparks DL, Scheff SW, Liu H, Landers T, Danner F, Coyne CM, Hunsaker JC: Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. J Neurol Sci 1996, 138:97-104
23. Joachim CL, Selkoe DJ: The seminal role of β-amyloid in the pathogenesis of Alzheimer's disease. Alz Dis Assoc Disord 1992, 6:7-34
24. Tagliavini F, Giaccone G, Frangione B, Bugianin O: Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals, Neurosci Lett 1988, 93:191-196
25. Delaere P, Duyckaerts C, Masters C, Beyreuther K, Piette F, Hauw JJ: Large amounts of neocortical βA4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci Lett 1990, 116:87-93
26. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P: Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med 1996, 2:93-95
27. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998, 95:6448-6453
28. Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Hozman TF, Finch CE: Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp Neurol 1995, 136:22-31
29. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ: β-Amyloid-(42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer's disease. Proc Natl Acad Sci USA 1993, 90:10836-10840
30. Ishii K, Tamaoka A, Mizusawa H, Shoji S, Ohtake T, Frazer P, Takahashi H, Tsuji S, Gearing M, Mizutani T, Yamada S, Kato M, St George-Hyslop P, Mirra S, Mori H: Aβ40 but not Aβ42 levels in cortex correlate with apolipoprotein E ∈4 allele dosage in sporadic Alzheimer's disease. Brain Res 1997, 748:250-252
31. Greenberg SM, Briggs ME, Hyman BT, Kokoris GJ, Takis C, Kanter DS, Kase CS, Pessin MS: Apolipoprotein E ∈4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996, 27:1333-1337
32. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM: Progression of cerebral amyloid angiopathy: accumulation of amyloid-β40 in affected vessels. J Neuropathol Exp Neurol 1998, 57:353-359
33. Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ: The apolipoprotein E ∈4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996, 47: 190-196